Cinclus Pharma Holding ABFRA:J8P +2.28%4 EV-to-FCF is -0.90 as of Jul. 08, 2026. GuruFocus rates FRA:J8P with a GF Score™ of 4/100. The stock has 3 warning signs investors should review. Among 563 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 177619.72% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cinclus Pharma Holding AB's Enterprise Value is €10.70 Mil.
Cinclus Pharma Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-11.92 Mil. Therefore, Cinclus Pharma Holding AB's EV-to-FCF for today is -0.90.
The historical rank and industry rank for Cinclus Pharma Holding AB's EV-to-FCF or its related term are showing as below:
FRA:J8P'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.46 Med: -2.51 Max: 0.36
Current: -0.76
During the past 5 years, the highest EV-to-FCF of Cinclus Pharma Holding AB was 0.36. The lowest was -8.46. And the median was -2.51.
FRA:J8P's EV-to-FCF is ranked worse than 100% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs FRA:J8P: -0.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cinclus Pharma Holding AB (FRA:J8P) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cinclus Pharma Holding AB's PE Ratio (TTM) for today is calculated as:
Cinclus Pharma Holding AB's share price for today is €0.986.
Cinclus Pharma Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cinclus Pharma Holding AB EV-to-FCF Related Terms
Cinclus Pharma Holding AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's EV-to-FCF falls into.
Cinclus Pharma Holding AB's current Enterprise Value is €10.70 Mil.
Cinclus Pharma Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cinclus Pharma Holding AB (FRA:J8P) has a EV-to-FCF of -0.90 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 563 companies in the Drug Manufacturers industry.
Is Cinclus Pharma Holding AB's EV-to-FCF too high?
Cinclus Pharma Holding AB's current EV-to-FCF is -0.90. Based on the distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 563 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 563 companies for EV-to-FCF. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median EV-to-FCF is 20.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current EV-to-FCF is -0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current EV-to-FCF of -0.90. The current EV-to-FCF is -0.90. Cinclus Pharma Holding AB's overall GF Score™ is 4/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current EV-to-FCF is -0.90 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
4GF Score
Get the complete analysis for FRA:J8P
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
